EUVIMEDObjevte EUVIMED
CrossrefInformační karta

Network analysis of FDA approved drugs and their targets

Avi Ma'ayan, Sherry L. Jenkins, Joseph Goldfarb, Ravi Iyengar

Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · 2007

DOI: 10.1002/msj.20002 ↗
AbstraktBibliografické údaje

Abstrakt

Abstract The global relationship between drugs that are approved for therapeutic use and the human genome is not known. We employed graph‐theory methods to analyze the Federal Food and Drug Administration (FDA) approved drugs and their known molecular targets. We used the FDA Approved Drug Products with Therapeutic Equivalence Evaluations 26 th Edition Electronic Orange Book (EOB) to identify all FDA approved drugs and their active ingredients. We then connected the list of active ingredients extracted from the EOB to those known human protein targets included in the DrugBank database and constructed a bipartite network. We computed network statistics and conducted Gene Ontology analysis on the drug targets and drug categories. We find that drug to drug‐target relationship in the bipartite network is scale‐free. Several classes of proteins in the human genome appear to be better targets for drugs since they appear to be selectively enriched as drug targets for the currently FDA approved drugs. These initial observations allow for development of an integrated research methodology to identify general principles of the drug discovery process. Mt Sinai J Med 74:27–32, 2007. © 2007 Mount Sinai School of Medicine

Znalosti, které odpovídají vaší práci.

Od bezplatného začátku přes osobní rešerše literatury až po kompletní Research Suite.

Zobrazit tarify →

Jsou zahrnuty všechny plné texty vydavatelů?

Ne. Bibliografické záznamy, abstrakty a plné texty jsou různé typy obsahu. To, zda je plný text dostupný, závisí na zdroji, Open Access a vašich stávajících licencích. Tarif EUVIMED nenahrazuje dodatečná vydavatelská práva.

Zobrazit tarify →